JP Morgan Chase
CRSP icon

JP Morgan Chase’s CRISPR Therapeutics CRSP Stock Holding History

JP Morgan Chase’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,200
Closed -$1.57M – 7444
2025
Q2 		$1.57M Buy
+32,200
New +$1.25M ﹤0.01% 4090
2025
Q1 		– Sell
-400
Closed -$15.7K – 7373
2024
Q4 		$15.7K Hold
400
– – ﹤0.01% 6299
2024
Q3 		$18.8K Hold
400
– – ﹤0.01% 6248
2024
Q2 		$21.6K Sell
400
-25,600
-98% -$1.48M ﹤0.01% 6115
2024
Q1 		$1.77M Buy
+26,000
New +$1.86M ﹤0.01% 3938
2023
Q1 		– Sell
-13,500
Closed -$549K – 6769
2022
Q4 		$549K Hold
13,500
– – ﹤0.01% 4452
2022
Q3 		$882K Hold
13,500
– – ﹤0.01% 4092
2022
Q2 		$820K Hold
13,500
– – ﹤0.01% 4240
2022
Q1 		$847K Buy
+13,500
New +$848K ﹤0.01% 4387
2019
Q4 		– Sell
-20,700
Closed -$848K – 5634
2019
Q3 		$848K Sell
20,700
-11,200
-35% -$535K ﹤0.01% 3922
2019
Q2 		$1.45M Buy
+31,900
New +$1.27M ﹤0.01% 3609
2019
Q1 		– Sell
-55,000
Closed -$1.57M – 5793
2018
Q4 		$1.57M Sell
55,000
-32,000
-37% -$1.11M ﹤0.01% 3453
2018
Q3 		$3.86M Buy
87,000
+37,000
+74% +$1.94M ﹤0.01% 2948
2018
Q2 		$2.94M Buy
+50,000
New +$2.85M ﹤0.01% 3112

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's CRSP Position: Q2 2026 in Review

JP Morgan Chase reduced its CRISPR Therapeutics (CRSP) stake by 5.7% in Q2 2026, selling an estimated $1.37M and leaving 431,669 shares worth $24.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

JP Morgan Chase first reported a position in CRSP in Q3 2017 and has held it in 35 quarters since. The position peaked at $92.8M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • JP Morgan Chase held 431,669 shares of CRISPR Therapeutics worth $24.6M as of Q2 2026.
  • JP Morgan Chase sold 25,970 CRISPR Therapeutics shares in Q2 2026, an estimated $1.37M.
  • CRISPR Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2040 holding.
  • JP Morgan Chase first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 35 quarters since.
  • JP Morgan Chase's CRISPR Therapeutics position peaked at $92.8M in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.